The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics
Open accessAbstract
At the time of writing this commentary (February 2020), the coronavirus COVID‐19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS‐CoV‐2 virus may take many months. Moreover, vaccines based on viral‐encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS‐CoV‐2 virus infections. This idea is based on observations that the angiotensin‐converting enzyme 2 (ACE2) very likely serves as the binding site for SARS‐CoV‐2, the strain implicated in the current COVID‐19 epidemic, similarly to strain SARS‐CoV implicated in the 2002–2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS‐CoV‐2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Cited by
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
COVID‐19 diagnosis and management: a comprehensive review
Pascarella, G., Strumia, A., Piliego, C., Bruno, F., Del Buono, R., Costa, F., Scarlata, S., & Agrò, F. E. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13091 · Cited by 1,369
Impact of sex and gender on COVID-19 outcomes in Europe
Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00304-9 · Cited by 1,306
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237
“[80,83] It is hoped that the results of the above mentioned NCT04312009 and NCT04311177 trials will answer this question.”
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Genotype and phenotype of COVID-19: Their roles in pathogenesis
Mousavizadeh, L., & Ghasemi, S. (2021) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.022 · Cited by 962
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
Wang, M.-Y., Zhao, R., Gao, L.-J., Gao, X.-F., Wang, D.-P., & Cao, J.-M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.587269 · Cited by 874
Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2
Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., & Zuo, W. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202001-0179le · Cited by 916
COVID-19 and diabetes: Knowledge in progress
Hussain, A., Bhowmik, B., & do Vale Moreira, N. C. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108142 · Cited by 796
Catanzaro, M., Fagiani, F., Racchi, M., Corsini, E., Govoni, S., & Lanni, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0191-1 · Cited by 605
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 592
Biswas, M., Rahaman, S., Biswas, T. K., Haque, Z., & Ibrahim, B. (2021) · Intervirology · doi:10.1159/000512592 · Cited by 504
Zimmermann, P., & Curtis, N. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320338 · Cited by 502
Obesity and diabetes as high‐risk factors for severe coronavirus disease 2019 (Covid‐19)
Zhou, Y., Chi, J., Lv, W., & Wang, Y. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3377 · Cited by 490
Danser, A. H. J., Epstein, M., & Batlle, D. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15082 · Cited by 457
de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-Luque, A., Laredo, L., Laosa, O., Centeno-Soto, G. A., Ángeles Gálvez, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31030-8 · Cited by 408
Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Han, Y., Lin, L., Ruan, L., & Li, T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa102 · Cited by 405
Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa433 · Cited by 403
Mehta, N., Kalra, A., Nowacki, A. S., Anjewierden, S., Han, Z., Bhat, P., Carmona-Rubio, A. E., Jacob, M., Procop, G. W., Harrington, S., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1855 · Cited by 400
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
Kuster, G. M., Pfister, O., Burkard, T., Zhou, Q., Twerenbold, R., Haaf, P., Widmer, A. F., & Osswald, S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa235 · Cited by 395
Iaccarino, G., Grassi, G., Borghi, C., Ferri, C., Salvetti, M., Volpe, M., Cicero, A. F. G., Minuz, P., Muiesan, M. L., Mulatero, P., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15324 · Cited by 392
Schiffrin, E. L., Flack, J. M., Ito, S., Muntner, P., & Webb, R. C. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa057 · Cited by 372
Pranata, R., Lim, M. A., Huang, I., Raharjo, S. B., & Lukito, A. A. (2020) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320320926899 · Cited by 346
Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians
Batah, S. S., & Fabro, A. T. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106239 · Cited by 319
“More details regarding the ACE and ACE2 pathways and their role with SARS-CoV-2 are detailed in Gurwitz D’s review [55].”
Farsalinos, K., Barbouni, A., & Niaura, R. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02355-7 · Cited by 294
Hasan, A., Paray, B. A., Hussain, A., Qadir, F. A., Attar, F., Aziz, F. M., Sharifi, M., Derakhshankhah, H., Rasti, B., Mehrabi, M., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1754293 · Cited by 293
Alanagreh, L., Alzoughool, F., & Atoum, M. (2020) · Pathogens · doi:10.3390/pathogens9050331 · Cited by 291
Al-Karmalawy, A. A., Dahab, M. A., Metwaly, A. M., Elhady, S. S., Elkaeed, E. B., Eissa, I. H., & Darwish, K. M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.661230 · Cited by 286
Tan, W., & Aboulhosn, J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.063 · Cited by 268
Cheng, Y.-W., Chao, T.-L., Li, C.-L., Chiu, M.-F., Kao, H.-C., Wang, S.-H., Pang, Y.-H., Lin, C.-H., Tsai, Y.-M., Lee, W.-H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108254 · Cited by 257
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications
Yamamoto, V., Bolanos, J. F., Fiallos, J., Strand, S. E., Morris, K., Shahrokhinia, S., Cushing, T. R., Hopp, L., Tiwari, A., Hariri, R., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200831 · Cited by 100
“Remdesivir, a broad spectrum antiviral [124] that inhibits RNA dependent RNA- polymerase, was successful in the control of in vitro SARS-CoV-2 [12, 125, 126], and it is hypothesized that it could be efficacious for prophylaxis and therapy of human coronavirus infections [48].”
BackgroundAngiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Saavedra, J. M. (2021) · Physiology · doi:10.1152/physiol.00036.2020 · Cited by 37
Metadata
- Authors
- Gurwitz, D.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2020-03-04
- Volume
- 81
- Issue
- 5
- Pages
- 537-540
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W3009723094
- Cited by
- 802
- References
- 33
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.